Heterozygosity for the S180L variant of MAL/TIRAP, a gene expressing an adaptor protein in the toll-like receptor pathway, is associated with lower risk of developing chronic chagas cardiomyopathy

Journal of Infectious Diseases

Volumn 199, Issue 12, 2009, Pages 1838-1845

  Ramasawmy, Rajendranath ^a,b,c   Cunha Neto, Edecio ^a,b   Fae, Kellen C ^a,b   Borba, Susan C P ^a,b   Teixeira, Priscila C ^a,b   Ferreira, Susanne C P ^a,b   Goldberg, Anna C ^b   Lanni, Barbara ^a   Mady, Charles ^a   Kalil, Jorge ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Instituto Nacional de Neurociência Translacional Ministério de Ciência e Tecnologia   (Brazil)

^c FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; PROTEIN TIRAP; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; INTERLEUKIN 1 RECEPTOR; MEMBRANE PROTEIN; TIRAP PROTEIN, HUMAN;

ADULT; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HEART LEFT VENTRICLE EJECTION FRACTION; HETEROZYGOSITY; HUMAN; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRYPANOSOMA CRUZI; CHRONIC DISEASE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; METABOLISM; PHYSIOLOGY; RISK FACTOR;

CHAGAS CARDIOMYOPATHY; CHRONIC DISEASE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HETEROZYGOTE; HUMANS; MEMBRANE GLYCOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, INTERLEUKIN-1; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 67650468816     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/599212     Document Type: Article

References (41)

1. World Health Organization (WHO). Control of Chagas disease: second report of the WHO Expert Committee. WHO technical report series, 905. Geneva, Switzerland: WHO, 2002.
2. Bestetti RB, Muccillo G. Clinical course of Chagas' heart disease: a comparison with dilated cardiomyopathy. Int J Cardiol 1997; 60:187-93.
3. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124:783-801.
4. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007; 7:353-64.
5. Yamamoto M, Sato S, Hemmi H, et al. Essential role for TIRAP in activation of the signalling cascade shared, by TLR2 and. TLR4. Nature 2002; 420:324-9.
6. Horng T, Barton GM, Flavell RA, Medzhitov R. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 2002;420:329-33.
7. Campos MA, Almeida IC, Takeuchi O, et al. Activation of Toll-like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite. J Immunol 2001; 167:416-23.
8. Ropert C, Gazzinelli RT. Regulatory role of Toll-like receptor 2 during infection with Trypanosoma cruzi. J Endotoxin Res 2004; 10:425-30.
9. Oliveira AC, Peixoto JR, de Arruda LB, et al. Expression of functional. TLR4 confers proinflammatory responsiveness to Trypanosoma cruzi glycoinositolphospholipids and higher resistance to infection with T. cruzi. J Immunol 2004; 173:5688-96.
10. Ouaissi A, Guilvard E, Delneste Y, et al. The Trypanosoma cruzi Tc52released protein induces human dendritic cell maturation, signals via Toll-like receptor 2, and confers protection against lethal infection. J Immunol 2002; 168:6366-74.
11. Petersen CA, Krumholz KA, Burleigh BA. Toll like receptor 2 regulates interleukin- 1ß-dependent cardiomyocyte hypertrophy triggered, by Trypanosoma cruzi. Infect Immun 2005; 73:6974-80.
12. Banca A, Santiago HC, Goldszmid R, Ropert C, Gazzinelli RT, Slier A. TLR9 and TLR2 signaling together account, for MyD88-dependent control of parasitemia in Trypanosoma cruzi infection. J Immunol 2006; 177:3515-9.
13. Gazzinelli RT, Denkers EY. Protozoan encounters with Toll like recep tor signalling pathways: implications for host parasitism. Nat Rev Immunol 2006; 6:895-906.
14. Zicker F, Netto JC, Zicker EM, Oliveira RM, Smith PG. Trypanosoma cruzi infection and electrocardiographic findings among active manual, workers: a population-based study in central Brazil. Int J Epidemiol 1990; 19:182-6.
15. Schröder NW, Schumann RR. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 2005; 5:156-64.
16. Hawn TR, Verbon A, Janer M, Zhao LP, Beutler B, Aderem A. Toll-like receptor 4 polymorphisms are associated with resistance to Legionnaires' disease. Proc Natl Acad. Sci USA 2005; 102:2487-9.
17. Schröder NW, Diterich I, Zinke A, et al. Heterozygous Arg753Gln polymorphism of human TLR-2 impairs immune activation by Borrelia burgdorferi and protects from late stage Lyme disease. J Immunol 2005; 175:2534-40.
18. Lazarus R, Klimecki WT, Raby BA, et al. Single-nucleotide polymorphisms in the Toll-like receptor 9 gene (TLR9): frequencies, pairwise linkage disequilibrium, and haplotypes in three U.S. ethnic groups and exploratory case-control disease association studies. Genomics 2003; 81:85-91.
19. Mockenhaupt FP, Hamann L, von Gaertner C, et al. Common polymorphisms of Toll-like receptors 4 and 9 are associated, with the clinical manifestation of malaria during pregnancy. J Infect Dis 2006; 194:184-8.
20. Pierik M, Joossens S, Van Steen K, et al. Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel dis eases. Inflamm Bowel Dis 2006; 12:1-8.
21. Leoratti FMS, Farias L, Alves FP, et al. Variants in the Toll-like receptor pathway signaling are associated with clinical outcomes of malaria. J Infect Dis 2008; 198:772-80.
22. Johnson CM, LyIe EA, Omueti KO, et al. A common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy. J Immunol 2007; 178:7520-4.
23. Tantisira K, Klimecki WT, Lazarus R, et al. Toll-like receptor 6 gene (TLR6): single-nucleotide polymorphism frequencies and preliminary association with the diagnosis of asthma. Genes Immun 2004; 5:343-6.
24. Hawn TR, Verbon A, Lettinga KD, et al. A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires' disease. J Exp Med 2003; 198:156372.
25. Hawn TR, Dunstan SJ, Thwaites GE, et al. A polymorphism in ToIlinterleukin 1 receptor domain containing adaptor protein is associated with susceptibility to meningeal tuberculosis. J Infect Dis 2006; 194:1127-34.
26. Khor CC, Chapman SJ, Vannberg FO, et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bac teremia, malaria and tuberculosis. Nat Genet 2007; 39:523-8.
27. Ramasawmy R, Cunha Neto E, Fae KC, et al. The monocyte chemoat tractant, protein-1 gene polymorphism is associated with cardiomyopathy in human Chagas disease. Clin Infect Dis 2006; 43:305-11.
28. Faé KC, Drigo SA, Cunha Neto E, et al. HLA and ß myosin heavy chain do not influence susceptibility to Chagas disease cardiomyopathy. Microbes Infect 2000; 2:745-51.
29. Deghaide NH, Dantas RO, Donadi. EA. HLA class I and II profiles of patients presenting with Chagas' disease. Dig Dis Sci 1998; 43:246-52.
30. Ramasawmy R, Cunha-Neto E, Faé KC, et al. BATI, a putative anti inflammatory gene, is associated with chronic Chagas cardiomyopathy. J Infect Dis 2006; 193:1394-9.
31. Ramasawmy R, Fae KC, Cunha- Neto E, et al. Polymorphisms in the gene for lymphotoxin-a predispose to chronic Chagas cardiomyopathy. J Infect Dis 2007; 196:1836-43.
32. Ramasawmy R, Faé KC, Cunha-Neto E, et: al. Variants in the promoter region of IKBL/NFKBIL1 gene may mark susceptibility to the development of chronic Chagas' cardiomyopathy among Trypanosoma cruziinfected individuals. Mol Immunol 2008; 45:283-8.
33. Nejentsev S, T'hye T, Szeszko JS, et al. Analysis of association of the TfRAP (MAL) S180L variant: and tuberculosis in three populations. Nat Genet 2008; 40:261-2.
34. Castiblanco J, Varela DC, Castaño-Rodríguez N, Rojas-Villarraga A, Hincapié ME, Anaya JM. TIRAP (MAL) S180L polymorphism is a common protective factor against developing tuberculosis and systemic Iu pus erythematosus. Infect Genet Evol 2008; 8:541-4.
35. + lymphocytes. Am J Trop Med Hyg 1993; 48:637-44.
36. Abel LC, Rizas LV, Ianni B, et al. Chronic Chagas' disease cardiomyopathy patients display an increased IFN-y response to Trypanosoma cruzi infection. J Autoimmun 2001; 17:99-107.
37. Ferreira RC, Ianni BM, Abel LC, et al. Increased plasma levels of tumor necrosis factor-a in asymptomatic/"indeterminate" and Chagas disease cardiomyopathy patients. Mem Inst. Oswaldo Cruz 2003; 98:407-11.
38. Higuchi Mde L, Benvenuti LA, Martins Reis M, Metzger M. Pathophysiology of the heart in Chagas' disease: current status and new developments. Cardiovasc. Res 2003; 60:96-107.
39. Higuchi ML, De Morais CF, Pereira Barreto AC, et al. The role of active myocarditis in the development of heart failure in chronic Chagas' disease: a study based on endomyocardial biopsies. Clin Cardiol 1987; 10: 6657-70.
40. Campos MA, Closel M, Valente EP, et al. Impaired production of pro inflammatory cytokines and host resistance to acute infection with Trypanosoma cruzi in mice lacking functional myeloid differentiation factor 88. J Immunol 2004; 172:1711-8.
41. Marinho CR, D'Império Lima MR, Grisotto MG, Alvarez JM. Influence of acute phase parasite load on pathology, parasitism, and activation of the immune system at the late chronic phase of Chagas' disease. Infect Immun 1999; 67:308-18